反応式
Cl[C:2]1[CH:3]=[C:4]([NH:21][C:22]2[CH:26]=[CH:25][O:24][N:23]=2)[C:5]2[N:6]([C:8]([C:11]([NH:13][C:14]3[CH:19]=[CH:18][N:17]=[CH:16][C:15]=3[F:20])=[O:12])=[CH:9][N:10]=2)[N:7]=1.[C@H:27]1([NH2:34])[CH2:32][CH2:31][C@H:30]([NH2:33])[CH2:29][CH2:28]1>CN1C(=O)CCC1>[NH2:33][C@H:30]1[CH2:31][CH2:32][C@H:27]([NH:34][C:2]2[CH:3]=[C:4]([NH:21][C:22]3[CH:26]=[CH:25][O:24][N:23]=3)[C:5]3[N:6]([C:8]([C:11]([NH:13][C:14]4[CH:19]=[CH:18][N:17]=[CH:16][C:15]=4[F:20])=[O:12])=[CH:9][N:10]=3)[N:7]=2)[CH2:28][CH2:29]1参加物
4
反応条件
- 温度
- 110 °C
実験手順
A mixture of 6-chloro-N-(3-fluoropyridin-4-yl)-8-(isoxazol-3-ylamino)imidazo[1,2-b]pyridazine-3-carboxamide (20 mg, 0.054 mmol) and trans-cyclohexane-1,4-diamine (61.1 mg, 0.535 mmol) in NMP (0.4 mL) was heated at 110° C. overnight, then cooled to room temperature. The resulting mixture was purified by reversed-phase preparative HPLC. The desired fractions were concentrated and dried to give 18.7 mg of 6-((trans-4-aminocyclohexyl)amino)-N-(3-fluoro-4-pyridinyl)-8-(3-isoxazolylamino)imidazo[1,2-b]pyridazine-3-carboxamide as a beige solid. HPLC Rt=2.292 min (Chromolith SpeedROD 4.6×50 mm, 10-90% aqueous methanol containing 0.1% TFA, 4 min gradient, monitored at 220 nm), [M+1]=452.
後処理
- temperaturecooled to room temperature
- customThe resulting mixture was purified by reversed-phase preparative HPLC
- concentrationThe desired fractions were concentrated
- customdried
出典と根拠
- ORDレコード
- ord-64e1a7b60b0240f5a640595d7affc82a
- 出典データセット
- uspto-grants-2013_03
- 特許番号
- US08389527B2
関連ノート
読み込み中…